ITGAM + Extracellular Vesicles Trigger CD8 + T Cell Activation via S100a9‐Mediated Metabolic Reprogramming in Acute Kidney Injury
Journal of Extracellular Vesicles · 2026-11 · 15 (11)
DOI: 10.1002/jev2.70404 ↗Abstract
ABSTRACT Acute kidney injury (AKI) is a prevalent condition with limited therapeutic options, in which sustained renal injury driven by inflammation remains a central pathological challenge. Here, we identify a specific subset of extracellular vesicles (EVs) as the critical link translating early myeloid inflammation into metabolically fuelled CD8 + T cell pathogenicity. Using single‐EV surface proteomics via a proximity barcoding assay in a murine ischemia‐reperfusion injury model, we mapped the renal EV landscape and discovered a myeloid‐derived ITGAM + EV subset with markedly increased abundance after injury. Using a CD63‐PAGFP ITGAM‐KI reporter mouse that genetically enhances ITGAM + EV release, we further validated that these EVs interact with CD8 + T cells in the renal lymphatic niche, driving their pro‐inflammatory activation. Proteomic profiling pinpointed S100a9 as the functional cargo on these ITGAM + EVs. Mechanistically, EV‐delivered S100a9 stabilized the mitochondrial aspartate‐glutamate carrier Slc25a12 in recipient CD8 + T cells, thereby enhancing glutamate metabolism to fuel a pathogenic transcriptional program. Pharmacological inhibition of S100a9 with tasquinimod, combined with genetic loss of S100a9 in bone marrow‐derived myeloid cells, established the necessity of EV‐associated S100a9 in driving CD8 + T cell activation. Our findings establish ITGAM + EVs as essential mediators of pro‐metabolic and pro‐inflammatory signal in AKI and highlight the S100a9–Slc25a12 axis as a promising therapeutic target for intercepting sterile inflammation.
EUVIMED